The buying and selling of stock by a company’s insider give investors a sense that the stock will rise or fall in the future. NewAmsterdam Pharma Company NV shares valued at $15,639 were purchased by Topper James N on Sep 15 ’25. At $23.70 per share, Topper James N acquired 660 shares. The insider’s holdings grew to 3,028,524 shares worth approximately $80.95 million following the completion of this transaction.
Also, Kooij Louise Frederika sold 150,000 shares, netting a total of over 3,874,017 in proceeds. Following the sale of shares at $25.83 each, the insider now holds 15,000 shares.
Before that, Topper James N had added 1,260 shares to its account. In a trade valued at $31,487, the Director bought NewAmsterdam Pharma Company NV shares for $24.99 each. Upon closing the transaction, the insider’s holdings increased to 1,260 shares, worth approximately $80.93 million.
As published in their initiating research note from Wells Fargo on August 25, 2025, NewAmsterdam Pharma Company NV [NAMS] has been an Overweight and the price target has been revised to $45. Analysts at Goldman started covering the stock with ‘”a Neutral”‘ outlook in a report released in mid July. As of June 17, 2025, Citigroup has initiated its “Buy” rating for NAMS. Earlier on June 10, 2025, Stifel initiated its rating. Their recommendation was “a Buy” for NAMS stock.
Analyzing NAMS Stock Performance
On last trading session, NewAmsterdam Pharma Company NV [NASDAQ: NAMS] rose 9.15% to $26.73. The stock’s lowest price that day was $24.95, but it reached a high of $26.75 in the same session. During the last five days, there has been a surge of approximately 0.49%. Over the course of the year, NewAmsterdam Pharma Company NV shares have jumped approximately 68.75%.
Is NewAmsterdam Pharma Company NV subject to short interest?
Stocks of NewAmsterdam Pharma Company NV saw a sharp rise in short interest on 2025-08-29 jumping by 0.32 million shares to 7.5 million. Data from Yahoo Finance shows that the short interest on 2025-07-31 was 7.18 million shares. A jump of 4.24% in short interest reflects a negative sentiment towards the stock. Despite the fact that short shares comprise just 9.19 of the overall float, the days-to-cover ratio (short ratio) jumped to 9.19.
Which companies own the most shares of NewAmsterdam Pharma Company NV (NAMS)?
In terms of NewAmsterdam Pharma Company NV share price expectations, FactSet research, analysts set an average price target of 45 in the next 12 months, up nearly 83.75% from the previous closing price of $24.49. Analysts anticipate NewAmsterdam Pharma Company NV stock to reach 45 by 2025, with the lowest price target being 45. In spite of this, 1 analysts ranked NewAmsterdam Pharma Company NV stock as Buy at the end of 2025. On June 04, 2025, Cantor Fitzgerald assigned a price target of “an Overweight” to the stock and initiated coverage with a $42.
